

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:

I13V100%  
pos=11,001 • K14KR91%  
N:100% N:100% pos=14,252 • K20I100%  
pos=21,002 • E35DN91%  
G:12% N:100% pos=27,333 • M36I100%  
pos=27,302 • R41K100%  
pos=27,003 • R57RK91%  
N:100% N:100% pos=29,073 • H69K100%  
pos=34,908 • V82VI100%  
N:100% G:100% pos=34,792 • L89M100%  
pos=37,729

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

- PR comments
- Other
- K20I is the consensus amino acid in subtype G and CRF02\_AG. In subtypes B and C, K20I is a PI-selected mutation of uncertain effects on currently used PIs.
  - V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses.

No drug resistance mutations were found for PI.

NRTI Mutations:None

NNRTI Mutations:None

RT Other Mutations:

E6S100%  
pos=14,505 • V35T100%  
pos=6,123 • E40ED91%  
G:100% G:100% pos=4,639 • K49R100%  
pos=3,399 • V60I100%  
pos=3,295 • K64KR91%  
N:100% G:100% pos=3,232 • K122E100%  
pos=1,393 • D123GN91%  
N:100% G:100% pos=3,362 • I135T100%  
pos=5,305 • K173L100%  
pos=5,625 • Q174K100%  
pos=3,623 • D177E100%  
pos=1,639 • V179I100%  
pos=1,605 • T200I100%  
pos=5,012 • Q207D100%  
pos=609 • V245E100%  
pos=392 • D150E100%  
pos=605 • A272P100%  
pos=492 • K277R100%  
pos=494 • T286A100%  
pos=602 • I293V100%  
pos=605 • P294V100%  
N:100% N:100% pos=605 • E312D100%  
pos=602 • K512R100%  
pos=752 • E514D100%  
pos=609 • S519N100%  
pos=3,282 • Q524K100%  
pos=3,292 • K527G100%  
pos=3,322 • E529D100%  
pos=3,302 •

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	Susceptible
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	Susceptible
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

- RT comments
- Other
- V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

INSTI Major Mutations:None

INSTI Accessory Mutations:None

IN Other Mutations:

K14R100%  
pos=1,305 • V31I100%  
pos=1,005 • V32I100%  
pos=1,005 • M50MT10%  
N:100% G:100% pos=1,262 • I60M100%  
pos=1,215 • I72V100%  
pos=573 • T112V100%  
pos=492 • I113V100%  
pos=492 • T124A100%  
pos=492 • T125A100%  
pos=492 • V126F100%  
pos=492 • G134N100%  
pos=502 • K136Q100%  
pos=502 • F139Y100%  
pos=1,003 • V201I100%  
pos=1,232 • I220IL10%  
N:100% G:100% pos=2,309 • Q221QH91%  
G:100% N:100% pos=1,179 • N222K100%  
pos=1,162 • L234I100%  
pos=1,205 • S255SN10%  
N:100% N:100% pos=3,307 • I268IL10%  
N:100% G:100% pos=3,001 • S283G100%  
pos=3,293 • R284G100%  
pos=3,293 • D286N100%  
pos=3,293

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

No drug resistance mutations were found for INSTI.